X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1255) 1255
index medicus (944) 944
male (665) 665
female (658) 658
pharmacology & pharmacy (489) 489
double-blind (483) 483
middle aged (470) 470
adult (465) 465
treatment outcome (445) 445
efficacy (350) 350
drug administration schedule (332) 332
aged (316) 316
infectious diseases (291) 291
drug therapy (290) 290
hiv infections - drug therapy (279) 279
safety (278) 278
double-blind method (227) 227
adolescent (217) 217
drug therapy, combination (205) 205
once-daily dolutegravir (195) 195
pharmacokinetics (191) 191
immunology (185) 185
medicine, general & internal (181) 181
respiratory system (181) 181
hiv (177) 177
care and treatment (175) 175
child (167) 167
randomized controlled trials as topic (155) 155
therapy (154) 154
open-label (153) 153
once daily (150) 150
clinical trials (146) 146
dosage and administration (136) 136
diabetes mellitus, type 2 - drug therapy (134) 134
research (134) 134
antiretroviral therapy (133) 133
pulmonary disease, chronic obstructive - drug therapy (131) 131
type 2 diabetes (131) 131
analysis (130) 130
administration, inhalation (127) 127
once-daily (126) 126
endocrinology & metabolism (121) 121
time factors (116) 116
dose-response relationship, drug (113) 113
obstructive pulmonary-disease (113) 113
asthma (112) 112
internal medicine (111) 111
raltegravir (110) 110
tiotropium (110) 110
antiretroviral-naive adults (109) 109
children (109) 109
drug combinations (109) 109
young adult (108) 108
health aspects (107) 107
animals (106) 106
medicine & public health (106) 106
anti-hiv agents - therapeutic use (105) 105
once-daily treatment (105) 105
hypoglycemic agents - therapeutic use (101) 101
placebo-controlled trial (100) 100
anti-hiv agents - administration & dosage (99) 99
hiv infections - virology (97) 97
quality of life (97) 97
chronic obstructive pulmonary disease (94) 94
hiv infection (94) 94
once-daily lixisenatide (94) 94
virology (92) 92
asthma - drug therapy (91) 91
diabetes (90) 90
microbiology (89) 89
clinical trials as topic (88) 88
lung diseases, obstructive (87) 87
adherence (86) 86
trial (86) 86
patients (85) 85
dolutegravir (84) 84
once-daily atomoxetine (84) 84
bronchodilator agents - therapeutic use (83) 83
protease inhibitors (83) 83
quality-of-life (83) 83
bronchodilator agents - administration & dosage (81) 81
combination (81) 81
adults (80) 80
aged, 80 and over (80) 80
initial treatment (80) 80
insulin (80) 80
viral load (80) 80
copd (79) 79
hiv-1 - drug effects (79) 79
human immunodeficiency virus--hiv (79) 79
review (79) 79
twice-daily lopinavir/ritonavir (79) 79
delayed-action preparations (78) 78
pediatrics (78) 78
psychiatry (78) 78
risk factors (78) 78
once-daily dosing (77) 77
severity of illness index (77) 77
prospective studies (75) 75
antiretroviral drugs (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1710) 1710
French (17) 17
German (17) 17
Spanish (12) 12
Japanese (4) 4
Korean (3) 3
Russian (3) 3
Portuguese (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2012, Volume 60, Issue 1, pp. 33 - 42
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article
The Lancet, ISSN 0140-6736, 02/2005, Volume 365, Issue 9459, pp. 573 - 578
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Journal Article